a Changes at week 24 (CD4-Caspase 3, CD4-Ki67, CD8-Caspase 3, CD8-Ki67) or week 48 (all other parameters) are changes from baseline predicted using mixed linear regression models. b p-value from parameter representing the difference in slopes between the 2 arms. c IL-1β, TNF-α and GM-CSF were also measured but most results were below limit of detection." eFigure 1. HIV RNA (log 10 copies/ml) Line of equality HIV RNA (log 10 copies/ml) Line of equality Individual points represent a patient's viral load result (on a logarithmic scale) at week 12 plotted against the same patient's result at week 0. The line shown is the line of equality. In the placebo group (n=40), values are evenly scattered around the line indicating that there is no systematic change in viral load between these visits. In the hydroxychloroquine group (n= 38), nearly all values lie above the line of equality, consistent with a systematic increase in viral load affecting most patients.
Individual points represent a patient's viral load result (on a logarithmic scale) at week 60 (off treatment) plotted against the same patient's result at week 48 (on treatment). In the placebo group (n=28), values are evenly scattered around the line indicating that there is no systematic change in viral load between these visits. In the hydroxychloroquine group (n=22), nearly all values lie below the line of equality, consistent with a systematic decrease in viral load affecting most patients following cessation of therapy.
